- Home
- ONCT vs NVFY Comparison
ONCT vs NVFY Comparison
Compare ONCT & NVFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONCT
- NVFY
- Stock Information
- Founded
- ONCT N/A
- NVFY 2003
- Country
- ONCT United States
- NVFY United States
- Employees
- ONCT N/A
- NVFY N/A
- Industry
- ONCT Biotechnology: Pharmaceutical Preparations
- NVFY Home Furnishings
- Sector
- ONCT Health Care
- NVFY Consumer Discretionary
- Exchange
- ONCT Nasdaq
- NVFY Nasdaq
- Market Cap
- ONCT 4.3M
- NVFY 3.6M
- IPO Year
- ONCT N/A
- NVFY N/A
- Fundamental
- Price
- ONCT $1.13
- NVFY $0.70
- Analyst Decision
- ONCT Buy
- NVFY
- Analyst Count
- ONCT 3
- NVFY 0
- Target Price
- ONCT $10.00
- NVFY N/A
- AVG Volume (30 Days)
- ONCT 156.9K
- NVFY 43.7K
- Earning Date
- ONCT 11-06-2024
- NVFY 11-14-2024
- Dividend Yield
- ONCT N/A
- NVFY N/A
- EPS Growth
- ONCT N/A
- NVFY N/A
- EPS
- ONCT N/A
- NVFY N/A
- Revenue
- ONCT $2,161,000.00
- NVFY $9,815,391.00
- Revenue This Year
- ONCT $113.76
- NVFY N/A
- Revenue Next Year
- ONCT N/A
- NVFY N/A
- P/E Ratio
- ONCT N/A
- NVFY N/A
- Revenue Growth
- ONCT 227.92
- NVFY N/A
- 52 Week Low
- ONCT $1.03
- NVFY $0.67
- 52 Week High
- ONCT $13.20
- NVFY $6.38
- Technical
- Relative Strength Index (RSI)
- ONCT 37.09
- NVFY 27.15
- Support Level
- ONCT $1.03
- NVFY $0.90
- Resistance Level
- ONCT $1.30
- NVFY $1.17
- Average True Range (ATR)
- ONCT 0.19
- NVFY 0.11
- MACD
- ONCT -0.01
- NVFY -0.03
- Stochastic Oscillator
- ONCT 13.70
- NVFY 5.64
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
About NVFY Nova Lifestyle Inc.
Nova Lifestyle Inc is a designer and lifestyle furniture company. It distributes and retails contemporary styled residential and commercial furniture. The firms marketing and sales platform offers retail as well as online selection and purchase fulfillment internationally. The company also sells managed a variety of bedding foundation components. Its collection of lifestyle furniture brands includes Diamond Sofa. The firm's products are made in the United States and Asia. Its customers mainly comprise distributors and retailers having specific geographic coverages that deploy middle to high-end private label home furnishings. The company operates in one business and industry segment: the design and sale of furniture.